Self-assembled Lipid Nanoparticles for Killing Triple Negative Breast Cancer Cells.

Area of Science:

• Biotechnology
• Nanomedicine
• Oncology

Background:

• Triple negative breast cancer (TNBC) is aggressive and hard to treat due to lack of ER, PR, and HER2.
• Current treatments for TNBC have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

• To develop and characterize self-assembled lipid nanoparticles (LNPs) from novel pegylated lipopeptides for targeting and killing TNBC cells.
• To evaluate the cellular uptake and efficacy of these LNPs in TNBC models.

Main Methods:

• Synthesis of pegylated lipopeptides with n-hexadecyl tails and RGDK/CGKRK targeting peptides.
• Formation and characterization of self-assembled LNPs using SEM.
• Assessment of cellular uptake in various cell lines (MCF-7, MDA-MB-231, HEK-293, HFF).
• Evaluation of TNBC cell killing efficacy using a JAK2 inhibitor (WP 1066) loaded LNPs.

Main Results:

• Self-assembled spherical LNPs were successfully formed.
• Pegylated CGKRK-lipopeptide LNPs showed significantly higher cellular uptake than pegylated RGDK-lipopeptide LNPs.
• WP 1066 loaded pegylated RGDK-lipopeptide LNPs killed approximately 60% of TNBC cells while only affecting 20% of non-cancerous HEK-293 cells.

Conclusions:

• Self-assembled pegylated lipopeptide LNPs are promising for TNBC therapy.
• These LNPs demonstrate targeted delivery and potent anti-cancer activity.
• The findings support further preclinical investigation in animal models for TNBC.